GLP-1 and the brain,

You were told Ozempic makes you lose weight. What you're not being told yet: the same peptide acts on the brain's reward circuits, reduces cravings for alcohol, nicotine and sugar, and shows promising signals against depression. GLP-1s may be becoming the most important therapeutic class since antidepressants.

Your brain also makes GLP-1

GLP-1 is produced by the L cells of the gut, but also by specific neurons in the brainstem. These neurons project to regions involved in reward, motivation and emotional regulation: the nucleus accumbens, the amygdala, the prefrontal cortex.

That is to say, GLP-1 is not only a satiety signal. It is a neurological modulator acting on the same reward circuits as drugs, alcohol and compulsive behaviours.

Beyond obesity: what clinical trials are exploring

Four distinct clinical fronts, at different stages of evidence. Swipe to compare.

Hunger and addiction share the same circuit

Cravings for food, alcohol, nicotine or sugar activate the same brain regions: the dopaminergic reward circuit. GLP-1 modulates this circuit by reducing the response to reward stimuli, whether a plate of fries or a glass of alcohol.

That is to say, semaglutide does not specifically target alcohol. It dampens the brain's response to anything that triggers a compulsive craving. This is both its strength and the reason some patients report a general loss of motivation as a side effect worth monitoring.

And what about food in all this?

If GLP-1s act on reward circuits, stimulating your natural GLP-1 through food is no longer just a question of weight. It is potentially a way to modulate your cravings, your mental energy and your resilience to compulsive behaviours.

This is not a therapeutic claim. It is a serious mechanistic hypothesis, consistent with what research is starting to document. The science is only at the beginning.